Related Experiment Video

Updated: Feb 18, 2026

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

18.2K

DJ-1 as a Therapeutic Target Against Cancer

Ji Cao1, Xiaobing Chen1, Meidan Ying1

  • 1Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

Advances in Experimental Medicine and Biology
|November 18, 2017
PubMed

Insights

DJ-1 is a gene linked to Parkinson's disease. New research shows DJ-1 also significantly impacts cancer development and progression, suggesting it as a potential therapeutic target for cancer treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Neuroscience

Background:

  • DJ-1 (gene) is implicated in cellular functions like oxidative stress response and mitochondrial regulation.
  • Mutations in DJ-1 are linked to early-onset Parkinson's disease.
  • Emerging evidence highlights DJ-1's role in tumor development and progression.

Purpose of the Study:

  • To review the current understanding of DJ-1's function in cancer.
  • To elucidate the mechanisms by which DJ-1 influences tumorigenesis.
  • To explore DJ-1 as a potential therapeutic target for anticancer strategies.

Main Methods:

  • Literature review of existing studies on DJ-1 in cancer.
  • Analysis of genetic and molecular data linking DJ-1 to tumor biology.
  • Synthesis of evidence regarding DJ-1's mechanistic roles in cancer.

Main Results:

  • DJ-1 participates in multiple cellular processes relevant to cancer, including stress response and mitochondrial function.
  • DJ-1's involvement in cancer spans initiation, development, and progression.
  • Specific mechanisms of DJ-1 action in cancer are being uncovered.

Conclusions:

  • DJ-1 is a significant factor in cancer biology, beyond its known role in Parkinson's disease.
  • Understanding DJ-1's mechanisms in cancer offers new avenues for therapeutic intervention.
  • DJ-1 represents a promising target for novel anticancer therapies.
Keywords:
Cancer therapeuticsDJ-1MechanismOncogeneTarget

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K